Kosmonova buran  

Nasdaq Buch
http://www.ariva.de/...om_usd0.001-aktie/times_and_sales?boerse_id=40 GrB  

Börsenbuch
http://www.ariva.de/...om_usd0.001-aktie/times_and_sales?boerse_id=40 GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  07.01.15      4,77      5,00§4,77 4,91 $ 49.735 244 T

GrB  

http://www.ariva.de/fate_therapeutics_com_usd0.001-aktie/kurs GrB  

::::::::: 4,98 $ ,GrB  

Nasdaq Börsenbuch
http://www.ariva.de/...om_usd0.001-aktie/times_and_sales?boerse_id=40 GrB  

Börsenbuch
http://www.ariva.de/...om_usd0.001-aktie/times_and_sales?boerse_id=40 GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  08.01.15      5,07      5,07§4,86 4,878 $ 29.311 145 T

GrB  

Börsenbuch
http://www.ariva.de/...om_usd0.001-aktie/times_and_sales?boerse_id=40 GrB  

::::::::::: 4,99 $ +2,30% +0,112 $
In Euro: 4,2134 € | Nasdaq, 09.01.15 ,GrB  

our shareholders. You will find key shareholder information and financial reports available to help put Fate Therapeutics, Inc.'s financial performance into perspective. http://ir.fatetherapeutics.com/
 

http://ir.fatetherapeutics.com/contactus.cfm GrB  

http://ir.fatetherapeutics.com/stockquote.cfm GrB  

http://ir.fatetherapeutics.com/financials.cfm GrB  

O Ja  O Nein  O Gutes Elternhaus  

O Ja  O Nein  O Quick Test  

O Ja  O Nein  O Alleinwixend  

ich danke

Grüsse und Küsse  

sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations. http://ir.fatetherapeutics.com/governance.cfm
 

http://ir.fatetherapeutics.com/governance.cfm GrB  

http://ir.fatetherapeutics.com/events.cfm GrB  

http://ir.fatetherapeutics.com/releases.cfm GrB  

Showcase 2015
Jan 6, 2015 http://ir.fatetherapeutics.com/releases.cfm  

We are leveraging our expertise in stem cell biology to develop innovative, disease-transforming cellular therapeutics for the treatment of patients with rare, life-threatening diseases.  Our therapeutic approach utilizes established pharmacologic modalities, such as small molecules and proteins, and targets well-characterized biological mechanisms to program cell function and fate.  We have particular interest in the areas of hematopoiesis and skeletal muscle biology, where the physiological role of adult stem cells has been well characterized and established through medical and/or biological precedent.  We are applying our novel approach to develop first-in-kind programmed cell therapeutic candidates for the treatment of hematologic malignancies, rare genetic disorders and degenerative diseases. http://fatetherapeutics.com/therapeutic-programs/